SCHEMBL6035540

SCHEMBL6035540

CCCc1nn(-c2ccc(C(F)(F)F)cn2)cc1CCCOc1c(CC(=O)O)cccc1OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.40
HCRTR1 O43613 3/20 0.39
HCRTR2 O43614 2/20 0.39
SMN1; SMN2 Q16637 4/20 0.37
TSHR P16473 1/20 0.37
PPARD Q03181 1/20 0.36
PPARA Q07869 1/20 0.36
KDM4E B2RXH2 2/20 0.35
LMNA P02545 2/20 0.35
APLNR P35414 1/20 0.35
SCN9A Q15858 2/20 0.35
PAX8 Q06710 1/20 0.34
GCGR P47871 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34
HSD17B10 Q99714 1/20 0.34
PDE10A Q9Y233 1/20 0.34
HPGD P15428 1/20 0.34
ITGB1 P05556 1/20 0.34
ITGA4 P13612 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6035208 0.98 HCRTR1 (0.38) PPARGHCRTR1HCRTR2SMN1; SMN2TSHR
SCHEMBL6036305 0.96 PPARG (0.39) PPARGHCRTR1HCRTR2SMN1; SMN2TSHR
SCHEMBL6035752 0.94 SMN1; SMN2 (0.41) PPARGSMN1; SMN2PPARDPPARAKDM4E
SCHEMBL6035210 0.92 GCGR (0.36) HCRTR1HCRTR2SMN1; SMN2KDM4ELMNA
SCHEMBL6035945 0.90 GCGR (0.35) PPARGHCRTR1HCRTR2SMN1; SMN2PPARD
SCHEMBL6035417 0.90 SMN1; SMN2 (0.36) PPARGHCRTR1HCRTR2SMN1; SMN2PPARD
SCHEMBL6034571 0.90 GCGR (0.35) PPARGHCRTR1HCRTR2SMN1; SMN2PPARD
SCHEMBL6035574 0.90 PPARD (0.42) PPARGPPARDPPARA
SCHEMBL6035863 0.89 PPARD (0.41) PPARGSMN1; SMN2PPARDPPARAKDM4E
SCHEMBL6035635 0.89 PPARG (0.40) PPARGHCRTR1HCRTR2SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 PPARG 1037/4885HCRTR1 215/4885HCRTR2 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.